Parkinson disease among patients treated for benign prostatic hyperplasia with alpha1 adrenergic receptor antagonists

Parkinson disease among patients treated for benign prostatic hyperplasia with alpha1 adrenergic receptor antagonists
J Clin Invest. 2021 Apr 6:145112. doi: 10.1172/JCI145112. Online ahead of print.ABSTRACTBACKGROUND: Recently the α1 adrenergic receptor antagonist terazosin was shown to activate PGK1, a possible target for the mitochondrial deficits in Parkinson disease related to its function as the initial enzyme in ATP synthesis during glycolysis. An epidemiologic study of terazosin users showed a lower incidence of Parkinson disease ... read more
Source: PubMedPublished on 2021-04-06By Rahul Sasane